131 related articles for article (PubMed ID: 21599608)
1. Enhancing immunotoxin cell-killing activity via combination therapy with ABT-737.
Fitzgerald DJ; Moskatel E; Ben-Josef G; Traini R; Tendler T; Sharma A; Antignani A; Mussai F; Wayne A; Kreitman RJ; Pastan I
Leuk Lymphoma; 2011 Jun; 52 Suppl 2(Suppl 2):79-81. PubMed ID: 21599608
[TBL] [Abstract][Full Text] [Related]
2. ABT-737 overcomes resistance to immunotoxin-mediated apoptosis and enhances the delivery of pseudomonas exotoxin-based proteins to the cell cytosol.
Traini R; Ben-Josef G; Pastrana DV; Moskatel E; Sharma AK; Antignani A; Fitzgerald DJ
Mol Cancer Ther; 2010 Jul; 9(7):2007-15. PubMed ID: 20587662
[TBL] [Abstract][Full Text] [Related]
3. Combination treatments with ABT-263 and an immunotoxin produce synergistic killing of ABT-263-resistant small cell lung cancer cell lines.
Mattoo AR; FitzGerald DJ
Int J Cancer; 2013 Feb; 132(4):978-87. PubMed ID: 22821746
[TBL] [Abstract][Full Text] [Related]
4. Immunotoxins for targeted cancer therapy.
Kreitman RJ
AAPS J; 2006 Aug; 8(3):E532-51. PubMed ID: 17025272
[TBL] [Abstract][Full Text] [Related]
5. Synergistic antitumor effects of 9.2.27-PE38KDEL and ABT-737 in primary and metastatic brain tumors.
Yu X; Dobrikov M; Keir ST; Gromeier M; Pastan IH; Reisfeld R; Bigner DD; Chandramohan V
PLoS One; 2019; 14(1):e0210608. PubMed ID: 30625226
[TBL] [Abstract][Full Text] [Related]
6. Synergistic cytotoxicity of a prostate cancer-specific immunotoxin in combination with the BH3 mimetic ABT-737.
Noll T; Schultze-Seemann S; Kuckuck I; Michalska M; Wolf P
Cancer Immunol Immunother; 2018 Mar; 67(3):413-422. PubMed ID: 29188305
[TBL] [Abstract][Full Text] [Related]
7. ABT-737 promotes the dislocation of ER luminal proteins to the cytosol, including pseudomonas exotoxin.
Antignani A; Sarnovsky R; FitzGerald DJ
Mol Cancer Ther; 2014 Jun; 13(6):1655-63. PubMed ID: 24739394
[TBL] [Abstract][Full Text] [Related]
8. Synergistic anticancer effects of the 9.2.27PE immunotoxin and ABT-737 in melanoma.
Risberg K; Fodstad Ø; Andersson Y
PLoS One; 2011; 6(9):e24012. PubMed ID: 21915275
[TBL] [Abstract][Full Text] [Related]
9. Immunotoxins in the treatment of refractory hairy cell leukemia.
Kreitman RJ; Pastan I
Hematol Oncol Clin North Am; 2006 Oct; 20(5):1137-51, viii. PubMed ID: 16990113
[TBL] [Abstract][Full Text] [Related]
10. Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737.
Oakes SR; Vaillant F; Lim E; Lee L; Breslin K; Feleppa F; Deb S; Ritchie ME; Takano E; Ward T; Fox SB; Generali D; Smyth GK; Strasser A; Huang DC; Visvader JE; Lindeman GJ
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2766-71. PubMed ID: 21768359
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia.
Kreitman RJ; Wilson WH; Bergeron K; Raggio M; Stetler-Stevenson M; FitzGerald DJ; Pastan I
N Engl J Med; 2001 Jul; 345(4):241-7. PubMed ID: 11474661
[TBL] [Abstract][Full Text] [Related]
12. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms.
Kuroda J; Kimura S; Andreeff M; Ashihara E; Kamitsuji Y; Yokota A; Kawata E; Takeuchi M; Tanaka R; Murotani Y; Matsumoto Y; Tanaka H; Strasser A; Taniwaki M; Maekawa T
Br J Haematol; 2008 Jan; 140(2):181-90. PubMed ID: 18028486
[TBL] [Abstract][Full Text] [Related]
13. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.
van Delft MF; Wei AH; Mason KD; Vandenberg CJ; Chen L; Czabotar PE; Willis SN; Scott CL; Day CL; Cory S; Adams JM; Roberts AW; Huang DC
Cancer Cell; 2006 Nov; 10(5):389-99. PubMed ID: 17097561
[TBL] [Abstract][Full Text] [Related]
14. Two Saporin-Containing Immunotoxins Specific for CD20 and CD22 Show Different Behavior in Killing Lymphoma Cells.
Polito L; Mercatelli D; Bortolotti M; Maiello S; Djemil A; Battelli MG; Bolognesi A
Toxins (Basel); 2017 May; 9(6):. PubMed ID: 28556822
[TBL] [Abstract][Full Text] [Related]
15. Recombinant immunotoxins for treating cancer.
FitzGerald DJ; Kreitman R; Wilson W; Squires D; Pastan I
Int J Med Microbiol; 2004 Apr; 293(7-8):577-82. PubMed ID: 15149034
[TBL] [Abstract][Full Text] [Related]
16. In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas.
Mason KD; Vandenberg CJ; Scott CL; Wei AH; Cory S; Huang DC; Roberts AW
Proc Natl Acad Sci U S A; 2008 Nov; 105(46):17961-6. PubMed ID: 19004807
[TBL] [Abstract][Full Text] [Related]
17. Approach to the patient after relapse of hairy cell leukemia.
Kreitman RJ; Fitzgerald DJ; Pastan I
Leuk Lymphoma; 2009 Oct; 50 Suppl 1(Suppl 1):32-7. PubMed ID: 19814696
[TBL] [Abstract][Full Text] [Related]
18. The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-βII depletion.
Biberacher V; Decker T; Oelsner M; Wagner M; Bogner C; Schmidt B; Kreitman RJ; Peschel C; Pastan I; Meyer Zum Büschenfelde C; Ringshausen I
Haematologica; 2012 May; 97(5):771-9. PubMed ID: 22180432
[TBL] [Abstract][Full Text] [Related]
19. Targeting CD22 in B-cell malignancies: current status and clinical outlook.
Sullivan-Chang L; O'Donnell RT; Tuscano JM
BioDrugs; 2013 Aug; 27(4):293-304. PubMed ID: 23696252
[TBL] [Abstract][Full Text] [Related]
20. Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors.
Mansfield E; Amlot P; Pastan I; FitzGerald DJ
Blood; 1997 Sep; 90(5):2020-6. PubMed ID: 9292538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
